Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral MMR Vaccine in Borderline Resectable/Unresectable Pancreatic Cancer
NCT07539155Phase 2Recruiting
- Sponsor
- University of Arkansas
- Start
- Jun 2026
- Primary completion
- Aug 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of M-M-R II in pancreatic cancer (PC), sponsored by University of Arkansas. Started Jun 2026; status: recruiting.
02
Drugs
M-M-R II
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07539155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07539155.